What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
His primary areas of study are Internal medicine, Colorectal cancer, Oncology, Irinotecan and Cetuximab.
The Internal medicine study combines topics in areas such as Gastroenterology and Surgery.
His Colorectal cancer research is multidisciplinary, relying on both Retrospective cohort study, Cancer research and Immunology.
His Oncology research incorporates themes from Clinical trial, Bevacizumab, Chemotherapy, Metastasis and Proportional hazards model.
The concepts of his Irinotecan study are interwoven with issues in Progressive disease, Surgical oncology and Progression-free survival.
His Cetuximab research focuses on Epidermal growth factor receptor and how it relates to Epidermal growth factor.
His most cited work include:
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial (1559 citations)
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer (1308 citations)
- Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest (884 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Internal medicine, Oncology, Colorectal cancer, Bevacizumab and Chemotherapy.
His research integrates issues of Gastroenterology and Surgery in his study of Internal medicine.
His studies deal with areas such as Neutropenia and Toxicity as well as Gastroenterology.
His research in Oncology intersects with topics in Cancer, KRAS, Phases of clinical research and First line treatment.
His Colorectal cancer research is multidisciplinary, relying on both Cancer research and Fluorouracil.
Bevacizumab is closely attributed to Single-nucleotide polymorphism in his research.
He most often published in these fields:
- Internal medicine (78.46%)
- Oncology (67.24%)
- Colorectal cancer (50.76%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (78.46%)
- Oncology (67.24%)
- Colorectal cancer (50.76%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Oncology, Colorectal cancer, Bevacizumab and FOLFOXIRI.
In general Internal medicine, his work in Irinotecan, Oxaliplatin, FOLFIRI and Chemotherapy is often linked to In patient linking many areas of study.
He studied Oncology and Cetuximab that intersect with Wild type.
His Colorectal cancer research includes elements of Placebo, Cancer research and Cohort.
His studies in Bevacizumab integrate themes in fields like Fluorouracil, Capecitabine, Phases of clinical research and Pooled analysis.
His FOLFOXIRI study combines topics from a wide range of disciplines, such as Febrile neutropenia and FOLFOX.
Between 2017 and 2021, his most popular works were:
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial (396 citations)
- Quantitative evidence for early metastatic seeding in colorectal cancer. (131 citations)
- Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial (114 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Alfredo Falcone mostly deals with Internal medicine, Oncology, Colorectal cancer, Bevacizumab and Irinotecan.
His Internal medicine study frequently draws connections to other fields, such as Gastroenterology.
Alfredo Falcone has researched Oncology in several fields, including Cetuximab, Clinical trial, Oxaliplatin and Hazard ratio.
Alfredo Falcone interconnects Placebo, Primary tumor, Chemotherapy and Cohort in the investigation of issues within Colorectal cancer.
His Bevacizumab study combines topics in areas such as Chemotherapy regimen, Phases of clinical research, Capecitabine and Meta-analysis, Pooled analysis.
Within one scientific family, Alfredo Falcone focuses on topics pertaining to Wild type under Irinotecan, and may sometimes address concerns connected to First line, Acquired resistance, Epidermal growth factor receptor and Transverse colon.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
